Boston Partners
LFCR icon

Boston Partners’s Lifecore Biomedical LFCR Stock Holding History

Boston Partners’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,175
Closed -$241K – 733
2025
Q1 		$241K Buy
+34,175
New +$212K ﹤0.01% 687
2024
Q3 		– Sell
-14,212
Closed -$72.9K – 738
2024
Q2 		$72.9K Sell
14,212
-5,462
-28% -$32.3K ﹤0.01% 699
2024
Q1 		$104K Buy
+19,674
New +$141K ﹤0.01% 766
2023
Q2 		– Sell
-93,558
Closed -$353K – 726
2023
Q1 		$353K Sell
93,558
-3,069
-3% -$17.1K ﹤0.01% 633
2022
Q4 		$626K Sell
96,627
-28,318
-23% -$233K ﹤0.01% 572
2022
Q3 		$1.11M Buy
124,945
+15,832
+15% +$161K ﹤0.01% 505
2022
Q2 		$1.09M Sell
109,113
-6,499
-6% -$64.3K ﹤0.01% 500
2022
Q1 		$1.34M Buy
115,612
+7,919
+7% +$88.2K ﹤0.01% 509
2021
Q4 		$1.2M Buy
107,693
+25,396
+31% +$246K ﹤0.01% 509
2021
Q3 		$759K Sell
82,297
-45,463
-36% -$495K ﹤0.01% 564
2021
Q2 		$1.44M Sell
127,760
-73,869
-37% -$852K ﹤0.01% 495
2021
Q1 		$2.14M Sell
201,629
-827
-0.4% -$9.3K ﹤0.01% 474
2020
Q4 		$2.2M Sell
202,456
-57,185
-22% -$591K ﹤0.01% 427
2020
Q3 		$2.52M Sell
259,641
-34,162
-12% -$325K ﹤0.01% 399
2020
Q2 		$2.34M Sell
293,803
-37,298
-11% -$385K ﹤0.01% 404
2020
Q1 		$2.88M Sell
331,101
-79,707
-19% -$829K 0.01% 393
2019
Q4 		$4.65M Buy
410,808
+54,577
+15% +$581K 0.01% 383
2019
Q3 		$3.87M Sell
356,231
-547,421
-61% -$5.96M 0.01% 401
2019
Q2 		$8.47M Buy
903,652
+842,413
+1,376% +$8.5M 0.01% 377
2019
Q1 		$752K Buy
+61,239
New +$748K ﹤0.01% 639
2018
Q3 		– Sell
-78,474
Closed -$1.17M – 750
2018
Q2 		$1.17M Sell
78,474
-352,075
-82% -$4.89M ﹤0.01% 725
2018
Q1 		$5.62M Buy
430,549
+47,304
+12% +$622K 0.01% 453
2017
Q4 		$4.83M Sell
383,245
-25,140
-6% -$318K 0.01% 507
2017
Q3 		$5.29M Buy
408,385
+23,730
+6% +$313K 0.01% 491
2017
Q2 		$5.71M Sell
384,655
-145,745
-27% -$2.03M 0.01% 458
2017
Q1 		$6.36M Buy
530,400
+76,890
+17% +$973K 0.01% 457
2016
Q4 		$6.26M Sell
453,510
-203,050
-31% -$2.81M 0.01% 458
2016
Q3 		$8.8M Sell
656,560
-63,460
-9% -$769K 0.01% 411
2016
Q2 		$7.75M Sell
720,020
-409,221
-36% -$4.51M 0.01% 428
2016
Q1 		$11.9M Sell
1,129,241
-228,839
-17% -$2.51M 0.02% 358
2015
Q4 		$16.1M Sell
1,358,080
-63,025
-4% -$774K 0.02% 335
2015
Q3 		$16.6M Buy
1,421,105
+216,965
+18% +$2.87M 0.03% 320
2015
Q2 		$17.4M Buy
1,204,140
+42,920
+4% +$619K 0.03% 328
2015
Q1 		$16.2M Buy
1,161,220
+168,899
+17% +$2.33M 0.02% 335
2014
Q4 		$13.7M Sell
992,321
-1,949
-0.2% -$25.2K 0.02% 357
2014
Q3 		$12.2M Buy
994,270
+54,810
+6% +$684K 0.02% 365
2014
Q2 		$11.7M Buy
939,460
+140,997
+18% +$1.66M 0.02% 367
2014
Q1 		$8.91M Buy
798,463
+471,203
+144% +$5.17M 0.02% 414
2013
Q4 		$3.97M Buy
+327,260
New +$3.91M 0.01% 544

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Boston Partners's LFCR Position: Q2 2025 in Review

Boston Partners sold out of Lifecore Biomedical (LFCR) in Q2 2025, closing a stake of 34,175 shares — an estimated $241K sold.

Boston Partners first reported a position in LFCR in Q4 2013 and held it in 39 quarters. The position peaked at $17.4M in Q2 2015. 86 funds tracked by Wall St. Rank hold LFCR as of Q2 2025.

  • Boston Partners reported no remaining Lifecore Biomedical position as of Q2 2025 after selling out during the quarter.
  • Boston Partners sold 34,175 Lifecore Biomedical shares in Q2 2025, an estimated $241K.
  • Boston Partners first reported a position in Lifecore Biomedical in Q4 2013 and held it in 39 quarters.
  • Boston Partners's Lifecore Biomedical position peaked at $17.4M in Q2 2015.
  • 86 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2025.

Based on Boston Partners's 13F filing for Q2 2025, filed 7 Aug 2025.